Navigation Links
Basic research leads to a novel cancer therapy

Cancer researcher Professor Axel Ullrich, a director at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth, and shrinks its tissue. This fundamental principle led to the development of SUTENT®, whose active ingredient is Sunitinib. SUTENT® was recently approved for clinical use in the United States, and it is expected to be brought onto the German market this year.

When particular growth factors are bound to specific receptors on the surface of a cell, this can cause the cell to propagate itself and build certain tissue similar to blood vessels. Worldwide, research into receptors has focused on a special class of proteins, called tyrosine kinases. They are responsible for causing the received signal to be transduced through a long signalling cascade into the nucleus, triggering cell division and multiplication. Signalling cascades are absolutely necessary, if various tissues - like blood vessels, nerve tissue, and connective tissue - are to be built up during the development of an organism and in the process of tissue regeneration.

Research has focussed on these tumour cell signalling cascades, because in cancers they are often disturbed. If there were a way to block growth factors, or the receptors on the cellular surface from tumour cells, that could lead to targeted therapies against cancers. Already in the 1980s, cancer researcher Axel Ullrich, then a scientist at Genentech (USA), working with colleagues in the UK and Israel, succeeded in describing the structure and function of a receptor for epidermal growth factor (EGF). Since then, tyrosine kinases and various growth factors have been at the focus of research and development of therapies against tumours.

Also, over a decade ago, a team led by Ullrich discovered that by interrupting the oxygen and nutrient supply to tumour cells, it is possible to inhibit
'"/>

Source:Max-Planck-Gesellschaft


Page: 1 2 3 4

Related biology news :

1. Distributed Basic Local Alignment Search Toolkit (W.ND-BLAST)
2. Basic work on E. coli identifies two new keys to regulation of bacterial gene expression
3. Columbia research lifts major hurdle to gene therapy for cancer
4. U of M researcher examines newly emerging deadly disease
5. NYU researchers simulate molecular biological clock
6. First atlas of key brain genes could speed research on cancer, neurological diseases
7. New research questions basic tenet of neuron function
8. Vital step in cellular migration described by UCSD medical researchers
9. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
10. UCSD researchers maintain stem cells without contaminated animal feeder layers
11. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Basic research leads novel cancer therapy

(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... acral melanomas the rare type of skin cancer that ... from other more common types of skin cancer, according to ... Pigment Cell & Melanoma Research . , Acral melanoma most ... feet, nail-beds and other hairless parts of the skin. Unlike ... UV damage from the sun. , The team, from the ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... in Japan may have developed a way to accurately predict ... the standard of care for chronic myeloid leukemia (CML). ... a journal of the American Association for Cancer Research. ... treatment of leukemia when it was approved in 2001. Yet ...
... July 28 BIO-key International, Inc. (OTC Bulletin Board: ... financial results for the second quarter and six month period ... the data presented in this release relative to the same ... fingerprint-based Biometrics Division. The company completed the sale of its ...
... required to smoke "electronic cigarettes" marketed as ... with possible adverse effects on human health, researchers ... The researchers used a smoking machine to compare ... five e-cigarette brands. They examined the vacuum required ...
Cached Biology News:New lab test could identify imatinib resistance 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 3BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 4BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 5BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 6BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 7Electronic cigarettes require more suction than conventional brands 2Electronic cigarettes require more suction than conventional brands 3Electronic cigarettes require more suction than conventional brands 4
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Sales Horizons, ... of its online sales skills training course ... skills. , MedTech clinical staff spend the majority of ... hospital, standalone medical center, or physician practice – providing ... But why stop there? Sales Horizons believes clinical staff ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
(Date:8/18/2014)... NEW YORK , August 18, 2014 /PRNewswire/ ... report published by Transparency Market Research "Life Science ... Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents ... Research and Academic Institutions, Clinical Laboratories, and Forensic ... and Forecast, 2013 - 2019", the global life ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
... and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD. ... ... Rancho Cordova, California Corporation, was formed in 2005 to develop and ... cancer, particularly diseases related to chromosomal telomere shortening. The Company worked ...
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... Company,s request for an,extension until December 3, 2008 ... capitalization requirement of $35 million or the alternative,requirement ... to remain,listed. There can be no assurance that ...
Cached Biology Technology:CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2